• OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • Search in
    • Categories
    • Tags
    • Date within
    • Views
    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Hungarian (Hungary)
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • Self Serve Advertising Portal - Buy Ads Now! No Contracts!
  • How To Self Record An Interview and Presentations
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Advertising Specifications
  • Publisher Calendar

  • Mobile
  • Connect Mobile App

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5613
  • Acute Myelogenous Leukemia 277
  • Bladder 111
  • Bone Metastases 7
  • Brain 90
  • Breast 585
  • Business Management 5
  • Cervical 18
  • Chronic Lymphocytic Leukemia 216
  • Chronic Myelogenous Leukemia 54
  • Colorectal 184
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 182
  • General 350
  • Genitourinary 6
  • Head and Neck 125
  • Help 3
  • Hematologic Malignancies 210
  • Hodgkin Lymphoma 34
  • Imaging 2
  • Immunotherapy 182
  • Kidney 399
  • Liver 41
  • Lung 108
  • Lymphoma 244
  • Melanoma and Skin 111
  • Multiple Myeloma 545
  • Myeloproliferative Disease 41
  • News 152
  • Non-Hodgkin Lymphoma 82
  • Non-Small Cell Lung Cancer 636
  • Other 525
  • Ovarian 67
  • Pancreatic 112
  • Patient Resources 51
  • Pediatric 7
  • Prostate 306
  • Sarcoma 15
  • Sickle Cell 22
  • Small Cell Lung Cancer 83
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 10

  • Install
  • Play a Link
  • About
  • Contact
Jakob Lindberg, CEO of Oncopeptides on Clinical Trials for the Treatment of RRMM @oncopeptides #MM
0:04:27

Jakob Lindberg, CEO of Oncopeptides on Clinical Trials for the Treatment of RRMM @oncopeptides #MM

Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses the 5 clinical trials for the treatment of relapsed/refractory multiple myeloma: O-12-M1, Horizon, Ocean, Anchor and Bridge.

________________

Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.
 
Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to provide an update on the final study results and it can be found on-demand here. 
 
"The presentation of final data from our pivotal HORIZON study, with competitive results in triple-class refractory myeloma patients, represents the most important milestone for Oncopeptides to date. These data confirm that melflufen has a good efficacy and safety profile in triple-class refractory myeloma patients - a fast-growing patient population with significant unmet medical need and lack of approved treatments. The safety profile was consistent with previous melflufen studies with good tolerability and a low rate of non-haematological adverse events. We firmly believe that melflufen has the potential to become an important treatment option for patients with relapsed refractory multiple myeloma. Study physicians and clinical sites have been immensely supportive and with their help we are on schedule to submit the NDA for accelerated approval end of Q2 2020.”
 
"Furthermore, with the strong final results from HORIZON our Peptide-Drug Conjugate (PDC) platform has been validated. In today's webcast we will describe the PDC pipeline development to date and the possibilities this gives us," concludes Jakob Lindberg.
99 Views
3 years Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Multiple Myeloma

Bispecific Antibodies: Revolution in Oncology
Bispecific Antibodies: Revolution in Oncology
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
40 Views
Oncology Conferences
2 months Ago
A New Refractory Multiple Myeloma Treatment: SUCCESSOR-2 trial
A New Refractory Multiple Myeloma Treatment: SUCCESSOR-2 trial
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
73 Views
Oncology Conferences
3 months Ago
Multiple Myeloma Cancer Disparities, A Global Perspective on Drug Toxicity Trends
0:12:21
Multiple Myeloma Cancer Disparities, A Global Perspective on Drug Toxicity Trends
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
61 Views
Oncology Conferences
3 months Ago
Global Disparities in Multiple Myeloma: Insights from FAERS Analysis
0:12:21
Global Disparities in Multiple Myeloma: Insights from FAERS Analysis
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
279 Views
Oncology Conferences
3 months Ago
Teclistamab Long-term Response RR Multiple Myeloma
0:07:07
Teclistamab Long-term Response RR Multiple Myeloma
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
22 Views
Oncology Conferences
3 months Ago
Multiple Myeloma the Phase 3 SUCCESSOR-2 Trial MeziKd Verses Kd
0:14:15
Multiple Myeloma the Phase 3 SUCCESSOR-2 Trial MeziKd Verses Kd
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
146 Views
Oncology Conferences
3 months Ago
MonumenTAL-1 Results a Pivotal Phase 2 Trial of Talquetamab in RRMM
0:12:54
MonumenTAL-1 Results a Pivotal Phase 2 Trial of Talquetamab in RRMM
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
131 Views
Oncology Conferences
3 months Ago
Standard of Care the Safety and Efficacy of Cilta-cel for RRMM Patients
0:08:27
Standard of Care the Safety and Efficacy of Cilta-cel for RRMM Patients
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
38 Views
Oncology Conferences
3 months Ago
Idecabtagene Vicleucel Shows Effectiveness and Safety in High-Risk Multiple Myeloma Patients Krina Patel MD
0:07:56
Idecabtagene Vicleucel Shows Effectiveness and Safety in High-Risk Multiple Myeloma Patients Krina Patel MD
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
61 Views
Krina Patel, MD, MSc
5 months Ago
REGN5458: A Trial for Relapsed/Refractory Multiple Myeloma a BCMAxCD3 Bispecific Antibody Naresh Bumma MD
0:10:54
REGN5458: A Trial for Relapsed/Refractory Multiple Myeloma a BCMAxCD3 Bispecific Antibody Naresh Bumma MD
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
109 Views
Naresh Bumma, MD
5 months Ago
2023 ASH Multiple Myeloma Updates [Slides] - Lisa Lee, MD MOASC
0:25:21
2023 ASH Multiple Myeloma Updates [Slides] - Lisa Lee, MD MOASC
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
44 Views
Lisa Lee, MD 
7 months Ago
2023 ASH Multiple Myeloma [Slides] - Lisa Lee, MD MOASC
0:03:43
2023 ASH Multiple Myeloma [Slides] - Lisa Lee, MD MOASC
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
27 Views
Lisa Lee, MD 
7 months Ago

comments@oncologytube.com Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592 - 1 (951) 944-2173